GamaMabs is a privately held immuno-oncology biotechnology company specialized in the development of optimized monoclonal antibodies (mAb). Its lead program is GM102 (formerly 3C23K), a mAb targeting the receptor of the anti-Müllerian hormone (AMHR2) in gynecological cancers, currently in phase Ia/Ib stage. GM102 has increased tumor cell killing properties through the activation of immune system cells, thanks to its EMABling® glyco-engineering technology. Founded in June 2013 in Toulouse (France), GamaMabs employs 7 professionals with a sound and successful experience in preclinical and clinical development up to registration. GamaMabs has established collaborations with leading academic and private partners in order to develop its programs, such as Institut Gustave Roussy, Institut Curie, Institut Cochin, Institut de Recherche en Cancérologie de Montpellier (IRCM) or Mass General Hospital (Boston). GamaMabs values high-potential technologies initially developed by LFB BIOTECHNOLOGIES, a French Biopharma specialized in Hemostasis and Immunological Disorders. LFB developed two original patented platforms for the generation of mAbs with high efficiency (EMABling®) and/or long duration of action (HuMabFc), as well as a pipeline of several products stemming from those technologies. For strategic reason LFB decided to transfer some assets and rights to use its mAbs platforms and mAbs Oncology projects to GamaMabs. The main objective of GamaMabs is to develop its mAbs up to the stage of Clinical Proof of Concept.